HomeCompareSCVPF vs JNJ

SCVPF vs JNJ: Dividend Comparison 2026

SCVPF yields 3.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.1K in total portfolio value· pulled ahead in Year 5
10 years
SCVPF
SCVPF
● Live price
3.09%
Share price
$4.89
Annual div
$0.15
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.31
Full SCVPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SCVPF vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCVPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCVPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCVPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCVPF
Annual income on $10K today (after 15% tax)
$263.00/yr
After 10yr DRIP, annual income (after tax)
$0.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCVPF + JNJ for your $10,000?

SCVPF: 50%JNJ: 50%
100% JNJ50/50100% SCVPF
Portfolio after 10yr
$25.2K
Annual income
$2,344.86/yr
Blended yield
9.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SCVPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.6
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCVPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCVPFJNJ
Forward yield3.09%2.13%
Annual dividend / share$0.15$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.2K$30.3K
Annual income after 10y$0.31$4,689.40
Total dividends collected$312.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SCVPF vs JNJ ($10,000, DRIP)

YearSCVPF PortfolioSCVPF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,855$154.70$10,592$272.30+$263.00SCVPF
2$11,693$78.47$11,289$357.73+$404.00SCVPF
3$12,551$39.50$12,123$472.89+$428.00SCVPF
4$13,449$19.81$13,141$629.86+$308.00SCVPF
5← crossover$14,401$9.92$14,408$846.81$7.00JNJ
6$15,414$4.96$16,021$1,151.60$607.00JNJ
7$16,495$2.48$18,122$1,588.22$1.6KJNJ
8$17,651$1.24$20,930$2,228.20$3.3KJNJ
9$18,887$0.62$24,792$3,191.91$5.9KJNJ
10$20,210$0.31$30,274$4,689.40$10.1KJNJ

SCVPF vs JNJ: Complete Analysis 2026

SCVPFStock

The Siam Cement Public Company Limited, together with its subsidiaries, operates in the cement and building materials, chemicals, and packaging businesses in Thailand and internationally. It operates through SCG Cement and Green Solutions, SCG Smart Living and Distributorship and Retail, SCG Décor, SCG Chemicals SCGC, SCGP, and other segments. The SCG Cement and Green Solutions segment produces cement, ready-mixed concrete, precast and post-tension, industrial solutions, waste management services, 3D printing, and advanced materials. Its SCG Smart Living and Distributorship and Retail segment engages in manufacturing of construction materials, including roofing tiles, board and wood substitutions, landscape products, thermal insulation, and autoclaved aerated concrete, as well as housing-related products and services, including solar solutions, fresh air ventilation systems and ventilation systems, modular home building services, and end-to-end roofing solutions; and SCG Distribution and Retail engages in distribution and retailing of cement, building materials, and other home & living products, as well as provides international supply chain solutions, and invests in logistics businesses. The SCG Decor segment engages in production and distributing ceramic tiles, sanitary ware, and related products, services and solutions. Its SCG Chemicals SCGC segment manufactures and sells olefins, polyolefins, vinyl, other chemical products, and providing industrial service and solutions; and SCGP segment engages in integrated packaging of fiber packaging, packaging paper, consumer and performance packaging, and medical supplies and labware; as well as fibrous business consisting of foodservice packaging and pulp and paper products; and recycling of packaging material. The other segment engages in clean energy business, pertinent technologies, and investment in other business. The Siam Cement Public Company Limited was founded in 1913 and is headquartered in Bangkok, Thailand.

Full SCVPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SCVPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCVPF vs SCHDSCVPF vs JEPISCVPF vs OSCVPF vs KOSCVPF vs MAINSCVPF vs ABBVSCVPF vs MRKSCVPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.